uniQure To Submit BLA In Q3 2026 For AMT‑130 Huntington's Therapy After FDA Accepts 3‑Year Phase I/II Data As Basis For Accelerated Approval

Loading news article.

uniQure To Submit BLA In Q3 2026 For AMT‑130 Huntington's Therapy After FDA Accepts 3‑Year Phase I/II Data As Basis For Accelerated Approval | WAPE

Article summary